PharmaCell to Purchase Cell Therapy Production Facility from TiGenix
PharmaCell enters an agreement purchase TiGenix therapy production facility.
PharmaCell B.V., a CMO for cellular therapies and regenerative medicine in Europe, has entered into an agreement with TiGenix N.V. to purchase its therapy production facility at the Chemelot site in Sittard-Geleen, The Netherlands. TiGenix is a European cell therapy company with a marketed product for cartilage repair, ChondroCelect. TiGenix and PharmaCell have signed an agreement to purchase the shares of TiGenix B.V., which holds the manufacturing site, subject to certain closing conditions and intend to close the transaction in the coming months. PharmaCell will acquire the facility, including its employees in Production, QC, QA and other functions. ChondroCelect will continue to be manufactured at the facility as before under a long-term CMO agreement with PharmaCell.
Source: PharmaCell B.V.
EMA Recommends Imfinzi-Based Perioperative Regimen for Treating Resectable NSCLC
March 10th 2025The committee’s recommendation is based on results from a Phase III trial in which Imfinzi demonstrated a reduced risk of recurrence, progression, or death by 32% compared to neoadjuvant chemotherapy alone.
International Women’s Day 2025: A Promising Future for Gender Diversity in Pharma
March 8th 2025In an interview with BioPharm International®, Sheryl Johnson from Orbia Fluor & Energy Materials chats about gender diversity, how women are helping to advance innovation, sustainability challenges, and progress in the field of inhaled drugs.
